<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02856282</url>
  </required_header>
  <id_info>
    <org_study_id>205708</org_study_id>
    <nct_id>NCT02856282</nct_id>
  </id_info>
  <brief_title>Drug Utilization Study for Pirinase Hayfever Relief</brief_title>
  <official_title>Drug Utilization Study for Pirinase Hayfever Relief for Adults 0.05% Nasal Spray</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose is to obtain real-world information on how consumers are complying with the
      product labelling This study will coincide with the launch of Pirinase Hayfever Relief for
      Adults 0.05% Nasal Spray in the United Kingdom (UK).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 4, 2016</start_date>
  <completion_date type="Anticipated">July 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of consumers with 18 years of age or older</measure>
    <time_frame>Baseline-2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of consumers with use of not more than 2 sprays/nostril per day</measure>
    <time_frame>Baseline-2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of consumers with reduced dose of 1 spray/nostril per day if symptoms improve</measure>
    <time_frame>Baseline-2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of consumers who consulted Doctor before use in pregnant or breastfeeding woman</measure>
    <time_frame>Baseline-2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of consumers who consulted Doctor if symptoms do not improve after 7 days of use</measure>
    <time_frame>Baseline-2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of consumers taking HIV medications do not use the drug</measure>
    <time_frame>Baseline-2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of consumers who consulted doctor if medication is used more than 1 month continuously</measure>
    <time_frame>Baseline-2 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1537</enrollment>
  <condition>Rhinitis, Allergic, Seasonal</condition>
  <arm_group>
    <arm_group_label>Pirinase Hayfever Relief for Adults 0.05% Nasal Spray</arm_group_label>
    <description>Two sprays into each nostril once a day, preferably in the morning. Once symptoms are under control ,a maintenance dose of one spray may be used accordingly</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pirinase Hayfever Relief for Adults 0.05% Nasal Spray</intervention_name>
    <description>Aqueous suspension of 0.05% micronised fluticasone propionate.Each actuation contains 50 micrograms of fluticasone propionate</description>
    <arm_group_label>Pirinase Hayfever Relief for Adults 0.05% Nasal Spray</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        An all comers population (consumers who opt in at their own discretion) of approximately
        1,537 consumers, will be included in this study. Age, gender, and social backgrounds will
        be allowed to fall out naturally.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants will be required to review, and electronically sign a Participation
             Agreement prior to completing the online survey.

          -  Participants of any age may participate.

          -  Participants who have purchased and used Pirinase Hayfever Relief for Adults 0.05%
             Nasal Spray for at least 7 days and are willing to participate in the online survey.

          -  Participants of either gender may participate

        Exclusion Criteria:

          -  Anyone who is directly involved with medicines such as doctors, nurses, and
             pharmacists.

          -  Participants who decline participation in the online survey
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2016</study_first_submitted>
  <study_first_submitted_qc>August 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2016</study_first_posted>
  <last_update_submitted>May 3, 2018</last_update_submitted>
  <last_update_submitted_qc>May 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

